APTALIS PHARMA INC Research and Development Expense (Excluding Acquired in Process Cost)
APTALIS PHARMA INC reported Research and Development Expense (Excluding Acquired in Process Cost) of $15.75 million for the 3-month period ending 2011-12-31, per its 10-Q filed 2012-02-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2012-02-10
- APTALIS PHARMA INC research and development expense (excluding acquired in process cost) for the quarter ending 2011-12-31 was $15.75M, a 126.51% increase year-over-year.
- APTALIS PHARMA INC research and development expense (excluding acquired in process cost) for the quarter ending 2011-09-30 was $20.41M, a 191.75% increase year-over-year.
- APTALIS PHARMA INC research and development expense (excluding acquired in process cost) for the quarter ending 2011-06-30 was $19.64M, a 128.14% increase year-over-year.
- APTALIS PHARMA INC research and development expense (excluding acquired in process cost) for the quarter ending 2010-12-31 was $6.96M.
- APTALIS PHARMA INC research and development expense (excluding acquired in process cost) for fiscal 2011 was $57.99M, a 82.85% increase from fiscal 2010.
- APTALIS PHARMA INC research and development expense (excluding acquired in process cost) for fiscal 2010 was $31.71M, a 11.99% decline from fiscal 2009.
- APTALIS PHARMA INC research and development expense (excluding acquired in process cost) for fiscal 2009 was $36.04M.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|---|---|
| 2011-12-31 | $15.75M 10-Q · filed 2012-02-10 | $36.16M derived: sum of 2 quarters · filed 2012-02-10 | $55.81M derived: sum of 3 quarters · filed 2012-02-10 | |
| 2011-09-30 | $20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-20 | $40.05M derived: sum of 2 quarters · filed 2011-12-20 | $57.99M 10-K · filed 2011-12-20 | |
| 2011-06-30 | $19.64M 10-Q · filed 2011-08-12 | $37.58M 10-Q · filed 2011-08-12 | ||
| 2010-12-31 | $6.96M 10-Q · filed 2012-02-10 | $13.95M derived: sum of 2 quarters · filed 2012-02-10 | $22.56M derived: sum of 3 quarters · filed 2012-02-10 | |
| 2010-09-30 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-20 | $15.61M derived: sum of 2 quarters · filed 2011-12-20 | $31.71M 10-K · filed 2011-12-20 | |
| 2010-06-30 | $8.61M 10-Q · filed 2011-08-12 | $24.72M 10-Q · filed 2011-08-12 | ||
| 2009-09-30 | $36.04M 10-K · filed 2011-12-20 |